Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner

T. Egawa, T. Kubota, T. Furukawa, Y. Otani, M. Watanabe, T. Furukawa, K. Kumai, M. Kitajima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Taxanes and anthracyclines are active against breast cancer. In this study we investigated the combined antitumor activity of these drugs, with particular regard to sequence-dependency. Materials and Methods: The combined antitumor activity of docetaxel and tetrahydropyranyladriamycin (THP) against two human breast cancer xenografts was assessed using an in vitro histoculture drug-response assay. The sequence-dependency of the combined cytotoxicity was evaluated by isobologram. Results: A synergistic antitumor activity of combined docetaxel + THP was exhibited against the R-27 xenograft when docetaxel was given first or simultaneously with THP. However, this synergism was diminished when THP was used before docetaxel. While an additive effect of combined docetaxel + THP was observed against MX-1 xenograft when docetaxel was given first or simultaneously with THP, this effect was not marked using the THP/docetaxel sequence. Conclusion: Docetaxel increased the antitumor activity of THP, but only when administered before or simultaneously with THP.

Original languageEnglish
Pages (from-to)2597-2600
Number of pages4
JournalAnticancer research
Volume21
Issue number4 A
Publication statusPublished - 2001 Nov 24

Keywords

  • Breast cancer
  • Combination therapy
  • Docetaxel
  • Synergism
  • Tetrahydropyranyladriamycin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner'. Together they form a unique fingerprint.

  • Cite this

    Egawa, T., Kubota, T., Furukawa, T., Otani, Y., Watanabe, M., Furukawa, T., Kumai, K., & Kitajima, M. (2001). Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner. Anticancer research, 21(4 A), 2597-2600.